These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 28087588)

  • 41. Oral anticoagulant use in addition to antiplatelet therapy for secondary prevention in acute coronary syndrome: current perspectives.
    Turpie AG
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):963-76. PubMed ID: 25017622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials.
    Navarese EP; Verdoia M; Schaffer A; Suriano P; Kozinski M; Castriota F; De Servi S; Kubica J; De Luca G
    QJM; 2011 Jul; 104(7):561-9. PubMed ID: 21572108
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Superselective embolization of renal hemorrhage occurring after percutaneous coronary intervention.
    Favero L; Saccà S; Cernetti C; Pasquetto G; Nikas D; Reimers B
    Cardiovasc Revasc Med; 2009; 10(1):62-5. PubMed ID: 19159859
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Patterns of discharge antiplatelet therapy and late outcomes among 8,582 patients with bleeding during acute coronary syndrome: a pooled analysis from PURSUIT, PARAGON-A, PARAGON-B, and SYNERGY.
    Chan MY; Sun JL; Wang TY; Lopes RD; Jolicoeur ME; Pieper KS; Rao SV; Newby LK; Mahaffey KW; Harrington RA; Peterson ED
    Am Heart J; 2010 Dec; 160(6):1056-64, 1064.e2. PubMed ID: 21146658
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
    Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
    Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.
    Cairns JA; McMurtry MS
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S60-70. PubMed ID: 23790600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preventable deaths, never events, and comparative effectiveness: it is time for US cardiologist to switch to transradial.
    Gilchrist IC
    Catheter Cardiovasc Interv; 2009 Sep; 74(3):416-7. PubMed ID: 19681112
    [No Abstract]   [Full Text] [Related]  

  • 49. Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?
    Nguyen MC; Lim YL; Walton A; Lefkovits J; Agnelli G; Goodman SG; Budaj A; Gulba DC; Allegrone J; Brieger D;
    Eur Heart J; 2007 Jul; 28(14):1717-22. PubMed ID: 17562671
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Incorporation of bleeding as an element of the composite end point in clinical trials of antithrombotic therapies in patients with non-ST-segment elevation acute coronary syndrome: validity, pitfalls, and future approaches.
    Subherwal S; Ohman EM; Mahaffey KW; Rao SV; Alexander JH; Wang TY; Alexander KP; Hasselblad V; Roe MT
    Am Heart J; 2013 May; 165(5):644-54, 654.e1. PubMed ID: 23622901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/ stenting.
    Lip GY; Huber K; Andreotti F; Arnesen H; Airaksinen KJ; Cuisset T; Kirchhof P; Marín F;
    Thromb Haemost; 2010 Jan; 103(1):13-28. PubMed ID: 20062939
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial.
    Ducrocq G; Schulte PJ; Becker RC; Cannon CP; Harrington RA; Held C; Himmelmann A; Lassila R; Storey RF; Sorbets E; Wallentin L; Steg PG
    EuroIntervention; 2015 Nov; 11(7):737-45. PubMed ID: 25254357
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding?
    Binder RK; Lüscher TF
    Eur Heart J; 2015 May; 36(20):1207-11. PubMed ID: 25838437
    [No Abstract]   [Full Text] [Related]  

  • 54. Temporal Trends and Outcomes Associated with Major Bleeding in Acute Coronary Syndromes: A Decade-Long Perspective from the Acute Coronary Syndrome Israeli Surveys 2000-2010.
    Sabbag A; Guetta V; Fefer P; Matetzky S; Gottlieb S; Meisel S; Iakobishvili Z; Blatt A; Goldenberg I; Segev A
    Cardiology; 2015; 132(3):163-71. PubMed ID: 26279459
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Balancing thromboembolism and bleeding risks: insights from anticoagulation for prosthetic heart valves.
    Tay KH; Lane DA; Lip GYH
    Chest; 2009 Dec; 136(6):1451-1452. PubMed ID: 19995760
    [No Abstract]   [Full Text] [Related]  

  • 56. Correlation of inhibition of platelet aggregation with cardiovascular and bleeding outcomes in acute coronary syndromes.
    Wada R; Rohatagi S; Small D; Winters KJ; Salazar DE
    J Clin Pharmacol; 2010 Aug; 50(8):904-13. PubMed ID: 20147617
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet Inhibitors.
    Shifrin MM; Widmar SB
    Nurs Clin North Am; 2016 Mar; 51(1):29-43. PubMed ID: 26897422
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Coronary angioplasty in acute coronary syndromes: adjuvant drug therapy and management of the bleeding risk due to antithrombotic agents].
    Zagnoni S; Casella G; Musuraca AC; Calabrese D; Pavesi PC; Di Pasquale G
    G Ital Cardiol (Rome); 2010 Dec; 11(12 Suppl 3):34S-42S. PubMed ID: 21491738
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CardioPulse: Triple therapy for percutaneous coronary intervention in atrial fibrillation: a nightmare.
    Verheugt FW
    Eur Heart J; 2016 Jan; 37(4):326-7. PubMed ID: 27462673
    [No Abstract]   [Full Text] [Related]  

  • 60. Dual antiplatelet and oral anticoagulant therapy: increasing use and precautions for a hazardous combination.
    Hylek EM; Solarz DE
    JACC Cardiovasc Interv; 2008 Feb; 1(1):62-4. PubMed ID: 19393146
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.